Type 1 Diabetes
U.S. FDA approves Levemir for treatment of diabetes in children
Published in Medical Letter on the CDC and FDA, November 27th, 2005
Levemir is a long-acting form of insulin that provides up to a 24-hour duration of action and has been observed in studies with adults to cause little weight change.
Novo Nordisk will launch Levemir for adults and children within the next 8 months.
Levemir was studied in a randomized, controlled clinical study of 347 children and adolescents with type 1 diabetes. The children were treated with Levemir as the baseline or "basal" insulin and with rapid acting insulin...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anti-infectives
Antimicrobial use common in U.S. neonatal and pediatric intensive care patients - Avian Influenza
Evolution of H5N1 avian influenza viruses in Asia outlined - Genetics & Genomics
New measles genotype identified in Uganda - Influenza A Virus
Concerns raised about increasing adamantane resistance in influenza A viruses - Adenovirus
Vitronectin enhances tropism of adenovirus type 19 for the cornea - Aspergillosis
Data advance knowledge in aspergillosis research - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
